BioNTech and OncoC4’s gotistobart nearly doubles median survival in previously treated squamous NSCLC

This is a genuine new, forward-looking clinical milestone rather than price commentary: on September 14, 2026, BioNTech and OncoC4 reported first median overall-survival data from the non-pivotal stage 1 of the randomized PRESERVE-003 Phase 3 trial. The source provides the key quantitative results—median overall survival of 18.5 months with gotistobart versus 10.0 months with docetaxel, hazard ratio 0.56, and nominal p-value 0.0295—in patients with metastatic squamous NSCLC whose disease progressed after prior PD-(L)1 immunotherapy and platinum-based chemotherapy. The result is material for BioNTech’s oncology pipeline, but it is not yet a regulatory approval and the pivotal stage 2 portion remains ongoing, so importance is high but not maximal. Surprise is moderated because an August 27 source had already reported a positive interim survival result, although the current release provides the newly mature median survival estimate. Confidence in the core facts is high because they are stated directly in the current source; the timestamp uses the explicit announcement date with midnight UTC as a date-only estimate because the actual event time was not provided. BioNTech (BNTX) is directly affected, and WuXi Biologics (2269.HK) has a documented exclusive biologics development and manufacturing relationship with OncoC4 that could benefit if the program advances, so both are approved. Competitor approvals are omitted because any commercial displacement remains conditional on confirmation, regulatory approval, and adoption.